- Home
- INVH vs KLTOW Comparison
INVH vs KLTOW Comparison
Compare INVH & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVH
- KLTOW
- Stock Information
- Founded
- INVH 2012
- KLTOW N/A
- Country
- INVH United States
- KLTOW United States
- Employees
- INVH N/A
- KLTOW 3
- Industry
- INVH Real Estate
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INVH Finance
- KLTOW Health Care
- Exchange
- INVH Nasdaq
- KLTOW Nasdaq
- Market Cap
- INVH 21.1B
- KLTOW N/A
- IPO Year
- INVH 2017
- KLTOW 2022
- Fundamental
- Price
- INVH $32.31
- KLTOW $0.26
- Analyst Decision
- INVH Buy
- KLTOW
- Analyst Count
- INVH 17
- KLTOW 0
- Target Price
- INVH $38.26
- KLTOW N/A
- AVG Volume (30 Days)
- INVH 3.4M
- KLTOW N/A
- Earning Date
- INVH 07-23-2025
- KLTOW N/A
- Dividend Yield
- INVH 3.59%
- KLTOW N/A
- EPS Growth
- INVH N/A
- KLTOW N/A
- EPS
- INVH 0.78
- KLTOW N/A
- Revenue
- INVH $2,618,857,000.00
- KLTOW N/A
- Revenue This Year
- INVH $5.35
- KLTOW N/A
- Revenue Next Year
- INVH $3.74
- KLTOW N/A
- P/E Ratio
- INVH $41.50
- KLTOW N/A
- Revenue Growth
- INVH 6.04
- KLTOW N/A
- 52 Week Low
- INVH $29.37
- KLTOW N/A
- 52 Week High
- INVH $37.80
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- INVH 36.32
- KLTOW N/A
- Support Level
- INVH $32.01
- KLTOW N/A
- Resistance Level
- INVH $32.81
- KLTOW N/A
- Average True Range (ATR)
- INVH 0.54
- KLTOW 0.00
- MACD
- INVH -0.10
- KLTOW 0.00
- Stochastic Oscillator
- INVH 13.76
- KLTOW 0.00
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.